A study published in the New England Journal of Medicine, Feb. 9th, 2012, concluded that tai chi reduced balance impairments in those with mild to moderate severity Parkinson’[...]
The Agency for Health Care Research and Quality (AHRQ) recently updated their evidence-based findings on the effectiveness of bone health drugs in preventing fractures. In brief, b[...]
A recent study in Neurology found a link between the risk of having a stroke and future development of memory loss or cognitive decline. The link was strongly tied to high blood pr[...]
FDA reported in 2008 and 2009, with health alerts to providers and consumers, that bisphosphonates (Fosamax, Actonel, Boniva and Reclast) can cause bone and joint pain that lead to[...]
So far in the arsenal of bone health drugs used to treat osteoporosis we have, Evista (raloxifene); bisphosphonates such as Fosamax (alendronate), Actonel (risedronate), Boniva (ib[...]
A study published in the Archives of Internal Medicine, Feb. 14th, 2011, compared fracture risk-reduction of oral bisphosphonates, drugs like Fosamax (alendronate), Actonel (risedr[...]
One of my first experiences in working with older adults, in a retirement community where I could engage with them and learn from them on a day-to-day basis, started me on my journ[...]
FDA updated the warning label on Reclast (zoledronic acid), used to treat osteoporosis, regarding the drug causing acute renal (kidney) failure in high-risk patients. FDA warned to[...]
The FDA released an alert today (8/24/2011) warning against the use of Celexa (citalopram), a drug used to treat depression, at doses greater than 40mg per day due to a risk of abn[...]
We all know that depression left untreated is associated with higher risk for negative outcomes such as stroke, heart attack, dementia, poor self-care in those with diabetes, among[...]
